Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab in Metastatic or Recurrent HPV-Related Cervical Carcinoma
NCT01693783Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2012
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ipilimumab in Cervical Cancer (CC), sponsored by National Cancer Institute. Started Dec 2012; status: completed.
02
Drugs
ipilimumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT01693783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01693783.